Global Limb Girdle Muscular Dystrophy Market

Limb Girdle Muscular Dystrophy Comprehensive Study by Type (LGMD1, LGMD2), Application (Hospitals, Clinics, Others), Treatment Type (Occupational Therapy, Respiratory Therapy, Speech Therapy), Diagnosis (Biopsy, MRI, EMG, Electrocardiography) Players and Region - Global Market Outlook to 2030

Limb Girdle Muscular Dystrophy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Limb Girdle Muscular Dystrophy
Limb-girdle muscular dystrophy is a term used for a group of diseases that cause weakness and muscle wasting in the arms and legs. The muscles most affected are the ones closest to the body (proximal muscles), particularly the muscles of the shoulders, upper arms, pelvic area, and thighs. The severity, age of onset, and characteristics of limb-girdle muscular dystrophy vary between the many subtypes of the disease and may even be inconsistent within the same family. Signs and symptoms can appear first at any age and generally worsen over time, although in some cases they can remain mild. The common features of LGMDs are the weakness and atrophy of the limb-girdle muscles. However, the age at which symptoms appear, and the rate and severity of disease progression can vary. There are two main groups of LGMDs. These two groups, called LGMD1 and LGMD2, are classified according to their inheritance patterns: autosomal dominant and autosomal recessive. There are few studies that confirm the effectiveness of exercise in muscular dystrophy of the limb-girdle. However, studies have shown that exercise can actually cause permanent damage to muscles due to strong muscle contraction.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Limb Girdle Muscular Dystrophy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Myonexus Therapeutics, Inc. (United States), aTyr Pharma, Inc. (United States) and Sarepta Therapeutics (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Limb Girdle Muscular Dystrophy market by Type (LGMD1 and LGMD2), Application (Hospitals, Clinics and Others) and Region.



On the basis of geography, the market of Limb Girdle Muscular Dystrophy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Occupational Therapy will boost the Limb Girdle Muscular Dystrophy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Biopsy will boost the Limb Girdle Muscular Dystrophy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Awareness Campaigns for LGMD and Emerging Demand from Economies

Market Growth Drivers:
Rising Disease Burden of Limb-Girdle Muscular Dystrophy, Growing Incidences of Orthopedic Disorders and Rising Geriatric Population and Unhealthy Lifestyle Habits

Challenges:
Growing Acceptance of Acupuncture and Yoga

Restraints:
Higher Cost and Maintenance of Physiotherapy Machines

Opportunities:
Rapid Technological Advancements & Product Innovation, Increasing Awareness among People and With the Government’s Urgency for the Treatment of the Disease and Increasing Investments in Biopharmaceutical R&D to Release Novel Disease Therapies

Market Leaders and their expansionary development strategies
In January 2023,Sarepta Therapeutics acquires gene therapy asset for Limb-Girdle Muscular Dystrophy Sarepta Therapeutics, a company specializing in gene therapies for neuromuscular diseases, acquired a gene therapy asset called SRP-9041 from Applied Genetic Technologies. SRP-9041 is being developed for the treatment of LGMD2E, another subtype of LGMD caused by mutations in the TCAP gene.
In February 2023, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the first patient has been dosed in Study SRP-9003-102. Also known as VOYAGENE, Study 9003-102 is a phase 1 study of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E). VOYAGENE is a U.S.-only study enrolling ambulant patients aged 18 years or older and non-ambulant patients, ages 4-50 years, using clinical process SRP-9003 material.


Key Target Audience
Providers of Limb-Girdle Muscular Dystrophy, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • LGMD1
  • LGMD2
By Application
  • Hospitals
  • Clinics
  • Others
By Treatment Type
  • Occupational Therapy
  • Respiratory Therapy
  • Speech Therapy

By Diagnosis
  • Biopsy
  • MRI
  • EMG
  • Electrocardiography

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Disease Burden of Limb-Girdle Muscular Dystrophy
      • 3.2.2. Growing Incidences of Orthopedic Disorders
      • 3.2.3. Rising Geriatric Population and Unhealthy Lifestyle Habits
    • 3.3. Market Challenges
      • 3.3.1. Growing Acceptance of Acupuncture and Yoga
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness Campaigns for LGMD
      • 3.4.2. Emerging Demand from Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Limb Girdle Muscular Dystrophy, by Type, Application, Treatment Type, Diagnosis and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Limb Girdle Muscular Dystrophy (Value)
      • 5.2.1. Global Limb Girdle Muscular Dystrophy by: Type (Value)
        • 5.2.1.1. LGMD1
        • 5.2.1.2. LGMD2
      • 5.2.2. Global Limb Girdle Muscular Dystrophy by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Limb Girdle Muscular Dystrophy by: Treatment Type (Value)
        • 5.2.3.1. Occupational Therapy
        • 5.2.3.2. Respiratory Therapy
        • 5.2.3.3. Speech Therapy
      • 5.2.4. Global Limb Girdle Muscular Dystrophy by: Diagnosis (Value)
        • 5.2.4.1. Biopsy
        • 5.2.4.2. MRI
        • 5.2.4.3. EMG
        • 5.2.4.4. Electrocardiography
      • 5.2.5. Global Limb Girdle Muscular Dystrophy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Limb Girdle Muscular Dystrophy (Price)
      • 5.3.1. Global Limb Girdle Muscular Dystrophy by: Type (Price)
  • 6. Limb Girdle Muscular Dystrophy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Myonexus Therapeutics, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ATyr Pharma, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sarepta Therapeutics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
  • 7. Global Limb Girdle Muscular Dystrophy Sale, by Type, Application, Treatment Type, Diagnosis and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Limb Girdle Muscular Dystrophy (Value)
      • 7.2.1. Global Limb Girdle Muscular Dystrophy by: Type (Value)
        • 7.2.1.1. LGMD1
        • 7.2.1.2. LGMD2
      • 7.2.2. Global Limb Girdle Muscular Dystrophy by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Limb Girdle Muscular Dystrophy by: Treatment Type (Value)
        • 7.2.3.1. Occupational Therapy
        • 7.2.3.2. Respiratory Therapy
        • 7.2.3.3. Speech Therapy
      • 7.2.4. Global Limb Girdle Muscular Dystrophy by: Diagnosis (Value)
        • 7.2.4.1. Biopsy
        • 7.2.4.2. MRI
        • 7.2.4.3. EMG
        • 7.2.4.4. Electrocardiography
      • 7.2.5. Global Limb Girdle Muscular Dystrophy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Limb Girdle Muscular Dystrophy (Price)
      • 7.3.1. Global Limb Girdle Muscular Dystrophy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Limb Girdle Muscular Dystrophy: by Type(USD Million)
  • Table 2. Limb Girdle Muscular Dystrophy LGMD1 , by Region USD Million (2018-2023)
  • Table 3. Limb Girdle Muscular Dystrophy LGMD2 , by Region USD Million (2018-2023)
  • Table 4. Limb Girdle Muscular Dystrophy: by Application(USD Million)
  • Table 5. Limb Girdle Muscular Dystrophy Hospitals , by Region USD Million (2018-2023)
  • Table 6. Limb Girdle Muscular Dystrophy Clinics , by Region USD Million (2018-2023)
  • Table 7. Limb Girdle Muscular Dystrophy Others , by Region USD Million (2018-2023)
  • Table 8. Limb Girdle Muscular Dystrophy: by Treatment Type(USD Million)
  • Table 9. Limb Girdle Muscular Dystrophy Occupational Therapy , by Region USD Million (2018-2023)
  • Table 10. Limb Girdle Muscular Dystrophy Respiratory Therapy , by Region USD Million (2018-2023)
  • Table 11. Limb Girdle Muscular Dystrophy Speech Therapy , by Region USD Million (2018-2023)
  • Table 12. Limb Girdle Muscular Dystrophy: by Diagnosis(USD Million)
  • Table 13. Limb Girdle Muscular Dystrophy Biopsy , by Region USD Million (2018-2023)
  • Table 14. Limb Girdle Muscular Dystrophy MRI , by Region USD Million (2018-2023)
  • Table 15. Limb Girdle Muscular Dystrophy EMG , by Region USD Million (2018-2023)
  • Table 16. Limb Girdle Muscular Dystrophy Electrocardiography , by Region USD Million (2018-2023)
  • Table 17. South America Limb Girdle Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 18. South America Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 19. South America Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 20. South America Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 21. South America Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 22. Brazil Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 23. Brazil Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 24. Brazil Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 25. Brazil Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 26. Argentina Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 27. Argentina Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 28. Argentina Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 29. Argentina Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 30. Rest of South America Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 33. Rest of South America Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 34. Asia Pacific Limb Girdle Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 38. Asia Pacific Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 39. China Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 40. China Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 41. China Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 42. China Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 43. Japan Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 44. Japan Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 45. Japan Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 46. Japan Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 47. India Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 48. India Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 49. India Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 50. India Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 51. South Korea Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 52. South Korea Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 53. South Korea Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 54. South Korea Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 55. Taiwan Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 56. Taiwan Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 57. Taiwan Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 58. Taiwan Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 59. Australia Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 60. Australia Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 61. Australia Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 62. Australia Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 67. Europe Limb Girdle Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 68. Europe Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 69. Europe Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 70. Europe Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 71. Europe Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 72. Germany Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 73. Germany Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 74. Germany Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 75. Germany Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 76. France Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 77. France Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 78. France Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 79. France Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 80. Italy Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 81. Italy Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 82. Italy Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 83. Italy Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 84. United Kingdom Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 87. United Kingdom Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 88. Netherlands Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 89. Netherlands Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 90. Netherlands Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 91. Netherlands Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 92. Rest of Europe Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 95. Rest of Europe Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 96. MEA Limb Girdle Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 97. MEA Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 98. MEA Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 99. MEA Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 100. MEA Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 101. Middle East Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 102. Middle East Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 103. Middle East Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 104. Middle East Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 105. Africa Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 106. Africa Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 107. Africa Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 108. Africa Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 109. North America Limb Girdle Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 110. North America Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 111. North America Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 112. North America Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 113. North America Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 114. United States Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 115. United States Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 116. United States Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 117. United States Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 118. Canada Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 119. Canada Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 120. Canada Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 121. Canada Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 122. Mexico Limb Girdle Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 123. Mexico Limb Girdle Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 124. Mexico Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2018-2023)
  • Table 125. Mexico Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2018-2023)
  • Table 126. Limb Girdle Muscular Dystrophy: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Limb Girdle Muscular Dystrophy: by Type(USD Million)
  • Table 131. Limb Girdle Muscular Dystrophy LGMD1 , by Region USD Million (2025-2030)
  • Table 132. Limb Girdle Muscular Dystrophy LGMD2 , by Region USD Million (2025-2030)
  • Table 133. Limb Girdle Muscular Dystrophy: by Application(USD Million)
  • Table 134. Limb Girdle Muscular Dystrophy Hospitals , by Region USD Million (2025-2030)
  • Table 135. Limb Girdle Muscular Dystrophy Clinics , by Region USD Million (2025-2030)
  • Table 136. Limb Girdle Muscular Dystrophy Others , by Region USD Million (2025-2030)
  • Table 137. Limb Girdle Muscular Dystrophy: by Treatment Type(USD Million)
  • Table 138. Limb Girdle Muscular Dystrophy Occupational Therapy , by Region USD Million (2025-2030)
  • Table 139. Limb Girdle Muscular Dystrophy Respiratory Therapy , by Region USD Million (2025-2030)
  • Table 140. Limb Girdle Muscular Dystrophy Speech Therapy , by Region USD Million (2025-2030)
  • Table 141. Limb Girdle Muscular Dystrophy: by Diagnosis(USD Million)
  • Table 142. Limb Girdle Muscular Dystrophy Biopsy , by Region USD Million (2025-2030)
  • Table 143. Limb Girdle Muscular Dystrophy MRI , by Region USD Million (2025-2030)
  • Table 144. Limb Girdle Muscular Dystrophy EMG , by Region USD Million (2025-2030)
  • Table 145. Limb Girdle Muscular Dystrophy Electrocardiography , by Region USD Million (2025-2030)
  • Table 146. South America Limb Girdle Muscular Dystrophy, by Country USD Million (2025-2030)
  • Table 147. South America Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 148. South America Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 149. South America Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 150. South America Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 151. Brazil Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 152. Brazil Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 153. Brazil Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 154. Brazil Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 155. Argentina Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 156. Argentina Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 157. Argentina Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 158. Argentina Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 159. Rest of South America Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 160. Rest of South America Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 161. Rest of South America Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 162. Rest of South America Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 163. Asia Pacific Limb Girdle Muscular Dystrophy, by Country USD Million (2025-2030)
  • Table 164. Asia Pacific Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 165. Asia Pacific Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 166. Asia Pacific Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 167. Asia Pacific Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 168. China Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 169. China Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 170. China Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 171. China Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 172. Japan Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 173. Japan Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 174. Japan Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 175. Japan Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 176. India Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 177. India Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 178. India Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 179. India Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 180. South Korea Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 181. South Korea Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 182. South Korea Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 183. South Korea Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 184. Taiwan Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 185. Taiwan Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 186. Taiwan Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 187. Taiwan Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 188. Australia Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 189. Australia Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 190. Australia Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 191. Australia Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 196. Europe Limb Girdle Muscular Dystrophy, by Country USD Million (2025-2030)
  • Table 197. Europe Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 198. Europe Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 199. Europe Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 200. Europe Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 201. Germany Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 202. Germany Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 203. Germany Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 204. Germany Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 205. France Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 206. France Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 207. France Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 208. France Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 209. Italy Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 210. Italy Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 211. Italy Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 212. Italy Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 213. United Kingdom Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 214. United Kingdom Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 215. United Kingdom Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 216. United Kingdom Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 217. Netherlands Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 218. Netherlands Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 219. Netherlands Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 220. Netherlands Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 221. Rest of Europe Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 222. Rest of Europe Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 223. Rest of Europe Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 224. Rest of Europe Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 225. MEA Limb Girdle Muscular Dystrophy, by Country USD Million (2025-2030)
  • Table 226. MEA Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 227. MEA Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 228. MEA Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 229. MEA Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 230. Middle East Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 231. Middle East Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 232. Middle East Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 233. Middle East Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 234. Africa Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 235. Africa Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 236. Africa Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 237. Africa Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 238. North America Limb Girdle Muscular Dystrophy, by Country USD Million (2025-2030)
  • Table 239. North America Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 240. North America Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 241. North America Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 242. North America Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 243. United States Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 244. United States Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 245. United States Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 246. United States Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 247. Canada Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 248. Canada Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 249. Canada Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 250. Canada Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 251. Mexico Limb Girdle Muscular Dystrophy, by Type USD Million (2025-2030)
  • Table 252. Mexico Limb Girdle Muscular Dystrophy, by Application USD Million (2025-2030)
  • Table 253. Mexico Limb Girdle Muscular Dystrophy, by Treatment Type USD Million (2025-2030)
  • Table 254. Mexico Limb Girdle Muscular Dystrophy, by Diagnosis USD Million (2025-2030)
  • Table 255. Limb Girdle Muscular Dystrophy: by Type(USD/Units)
  • Table 256. Research Programs/Design for This Report
  • Table 257. Key Data Information from Secondary Sources
  • Table 258. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Limb Girdle Muscular Dystrophy: by Type USD Million (2018-2023)
  • Figure 5. Global Limb Girdle Muscular Dystrophy: by Application USD Million (2018-2023)
  • Figure 6. Global Limb Girdle Muscular Dystrophy: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Limb Girdle Muscular Dystrophy: by Diagnosis USD Million (2018-2023)
  • Figure 8. South America Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 9. Asia Pacific Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 10. Europe Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 11. MEA Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 12. North America Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 13. Global Limb Girdle Muscular Dystrophy: by Type USD/Units (2018-2023)
  • Figure 14. Global Limb Girdle Muscular Dystrophy share by Players 2023 (%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Myonexus Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Myonexus Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 18. ATyr Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. ATyr Pharma, Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Sarepta Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 21. Sarepta Therapeutics (United States) Revenue: by Geography 2023
  • Figure 22. Global Limb Girdle Muscular Dystrophy: by Type USD Million (2025-2030)
  • Figure 23. Global Limb Girdle Muscular Dystrophy: by Application USD Million (2025-2030)
  • Figure 24. Global Limb Girdle Muscular Dystrophy: by Treatment Type USD Million (2025-2030)
  • Figure 25. Global Limb Girdle Muscular Dystrophy: by Diagnosis USD Million (2025-2030)
  • Figure 26. South America Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 27. Asia Pacific Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 28. Europe Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 29. MEA Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 30. North America Limb Girdle Muscular Dystrophy Share (%), by Country
  • Figure 31. Global Limb Girdle Muscular Dystrophy: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Myonexus Therapeutics, Inc. (United States)
  • aTyr Pharma, Inc. (United States)
  • Sarepta Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 242 Pages 51 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Limb Girdle Muscular Dystrophy Market Quantitative research analysis
Global Limb Girdle Muscular Dystrophy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Myonexus Therapeutics, Inc. (United States), aTyr Pharma, Inc. (United States) and Sarepta Therapeutics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Awareness Campaigns for LGMD " is seen as one of major influencing trends for Limb Girdle Muscular Dystrophy Market during projected period 2023-2030.
The Limb Girdle Muscular Dystrophy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Limb Girdle Muscular Dystrophy Market Report?

Have a Query? Click Here

Other Related Reports

Hypereosinophilic Syndrome Comprehensive Study by Treatment (Corticosteroids, Biological Therapy, Chemotherapy, Others), End-users (Hospitals, Clinics, Ambulatory Surgical Centres), Distribution Chan...
$ 3750
Niemann-Pick Disease Comprehensive Study by Type (Niemann-Pick Type A, Niemann-Pick Type B, Niemann-Pick Type C), Application (Genetic Testing and Diagnosis, Therapeutic Research), Treatment (Bone Ma...
$ 3650
Gliosarcoma Comprehensive Study by Type (Primary Gliosarcoma, Secondary Gliosarcoma), Treatment (Surgery, Radiation, Chemotherapy, Immunotherapy Drugs), End-users (Hospitals, Clinics, Ambulatory Surg...
$ 3450
Localized Scleroderma Comprehensive Study by Type (Morphea, Linear Scleroderma), Treatment (Creams, Ointments, Phototherapy, Steroids, Medication), End-users (Hospitals, Clinics, Others), Distributio...
$ 3650
Partial Epilepsy Comprehensive Study by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), End Use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers), End User (Adul...
$ 3500
Ataxia Comprehensive Study by Type (Cerebellar Ataxia, Sensory Ataxia, Vestibular Ataxia), Treatment (Adaptive Devices, Therapies (Physical Therapy, Occupational Therapy and Speech Therapy), Medicati...
$ 3750